Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.
Laboratory of Signal Transduction, Institutes of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia.
Clin Transl Med. 2022 May;12(5):e831. doi: 10.1002/ctm2.831.
Tissue damage caused by an infection oran autoimmune disease triggers degradation of collagen in the extracellular matrix (ECM), which further enhances inflammation. Therefore, improving ECM in aninflamed tissue can be exploited as a potential therapeutic target. A recentstudy emphasised an innovative approach against COVID-19 using polymerised type I collagen (PTIC) that improves disease severity through a hitherto unknownmechanism. In this paper, we provide an overview of potential mechanism thatmay explain the anti-inflammatory effect of collagen peptides. In addition,the paper includes a brief summary of possible side effect of collagendeposition in inflammatory diseases. Altogether, current knowledge suggeststhat collagen may potentially reduce the residual risk in inflammatorydiseases; however, the detailed mechanism remains elusive.
由感染或自身免疫性疾病引起的组织损伤会触发细胞外基质（ECM）中胶原蛋白的降解，从而进一步加剧炎症。因此，改善炎症组织中的 ECM 可以作为一种潜在的治疗靶点。最近的一项研究强调了一种针对 COVID-19 的创新方法，即使用聚合 I 型胶原蛋白（PTIC），该方法通过一种迄今为止未知的机制改善疾病严重程度。在本文中，我们提供了一个潜在机制的概述，该机制可能解释胶原蛋白肽的抗炎作用。此外，本文还简要总结了胶原蛋白在炎症性疾病中沉积的可能副作用。总的来说，目前的知识表明，胶原蛋白可能有潜力降低炎症性疾病的残留风险；然而，其详细机制仍不清楚。
